Galena Biopharma Inc (NASDAQ:GALE) shares are climbing almost 12% today after the biotech firm presented data from its Phase 1b trial that evaluates patient’s …
In a research report issued Monday, Maxim analyst Jason McCarthy reiterated a Buy rating on Galena Biopharma Inc (NASDAQ:GALE) with a price target of …
Maxim analyst Jason McCarthy is out with a research report on shares of bluebird bio Inc (NASDAQ:BLUE) discussing the aftermath of Mast Therapeutics’ (NYSEMKT:MSTX) …
Mast Therapeutics Inc (NYSEMKT:MSTX) announced yesterday that its phase III EPIC study results proved to be a “surprising disappointment,” after the firm’s pipeline …
All sickle cell community and investor eyes are on Mast Therapeutics (NYSEMKT:MSTX) this month, as MSTX prepares to roll out pivotal data from …
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares are tumbling 4% today, with sales for its generic copaxone (glatopa), an injection designed to treat patients with …
In the past week, Mast Therapeutics Inc (NYSEMKT:MSTX) stock has seen a price increase from $0.40 to $0.
Maxim analyst Jason McCarthy provides insight on shares of Galena Biopharma Inc (NASDAQ:GALE) after the company posted second-quarter results. While McCarthy reiterates a Buy …
Maxim analyst Jason McCarthy weighed in with a few insights on Inovio Pharmaceuticals Inc (NASDAQ:INO), after the company announced that the phase I study …
In a research note released Tuesday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX), with a $5.00 price target, …